Search research articles
Contact Us
Filters
Showing results (81-90 of 103) with videos related to
Page
of 11
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 14, 2016
Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy
H S Rugo, G N Hortobagyi, J Yao, et al.
The New England Journal of Medicine
|
May 1, 1998
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie
S Negrier, B Escudier, C Lasset, et al.
Melanoma Research
|
February 8, 2000
Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group
H Cure, P Souteyrand, R Ouabdesselam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 1998
Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial
A Ravaud, C Chevreau, L Cany, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 25, 2005
Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers
C Theodore, L Geoffrois, J B Vermorken, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 17, 2007
Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer
J-C Eymard, F Priou, A Zannetti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group
I Ray-Coquard, A Le Cesne, M T Rubio, et al.
British Journal of Cancer
|
March 24, 2012
Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis
S Bracarda, T E Hutson, C Porta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 25, 2016
How to report toxicity associated with targeted therapies?
B Cabarrou, J M Boher, E Bogart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape
B Escudier, C Chevreau, C Lasset, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 103) with videos related to
Sort By:
Page
of 11
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 14, 2016
Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy
H S Rugo, G N Hortobagyi, J Yao, et al.
The New England Journal of Medicine
|
May 1, 1998
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie
S Negrier, B Escudier, C Lasset, et al.
Melanoma Research
|
February 8, 2000
Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group
H Cure, P Souteyrand, R Ouabdesselam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 1998
Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial
A Ravaud, C Chevreau, L Cany, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 25, 2005
Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers
C Theodore, L Geoffrois, J B Vermorken, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 17, 2007
Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer
J-C Eymard, F Priou, A Zannetti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group
I Ray-Coquard, A Le Cesne, M T Rubio, et al.
British Journal of Cancer
|
March 24, 2012
Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis
S Bracarda, T E Hutson, C Porta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 25, 2016
How to report toxicity associated with targeted therapies?
B Cabarrou, J M Boher, E Bogart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape
B Escudier, C Chevreau, C Lasset, et al.
Page
of 11